Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768661 | 0.89 | CYP3A4 (0.46) | EGFRKMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL7773059 | 0.84 | EGFR (0.41) | EGFRPOLBKMT2AKDM4EHTT | |
| SCHEMBL7768664 | 0.81 | CYP3A4 (0.45) | EGFRKMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL7773051 | 0.80 | SMN1; SMN2 (0.43) | EGFRKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL7770742 | 0.80 | CYP3A4 (0.46) | EGFRKMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL7770194 | 0.78 | CYP3A4 (0.46) | KMT2AKDM4EHTTCYP3A4MEN1 | |
| SCHEMBL7765138 | 0.78 | CYP3A4 (0.44) | EGFRKMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL7770202 | 0.76 | MAPT (0.39) | CYP1A2CYP2C9CYP2C19KMT2ACYP3A4 | |
| SCHEMBL7768662 | 0.74 | CYP3A4 (0.46) | EGFRKMT2AKDM4EHTTSMN1; SMN2 | |
| SCHEMBL7770738 | 0.73 | NPY5R (0.51) | CYP1A2POLBCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259155-B2 | Phosphonic diester derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2007-08-21 | — | — | US | disclosed |
| US-20050256087-A1 | Phosphonic acid diester compounds | OTSUKA PHARMACEUTICAL FACTORY, INC. | 2005-11-17 | — | — | US | disclosed |
| EP-0749974-B1 | PHOSPHONIC DIESTER DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2001-06-27 | — | — | EP | disclosed |
| CN-1066739-C | Phosphonic diester deriv | OTSUKA PHARMA CO LTD (JP) | 2001-06-06 | — | — | CN | disclosed |
| US-5798344-A | TREATING DIABETES, HYPERLIPIDEMIA | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-08-25 | — | — | US | disclosed |
| CN-1147257-A | Phosphonic diester deriv | OTSUKA PHARMA CO LTD (JP) | 1997-04-09 | — | — | CN | disclosed |
| EP-0749974-A1 | PHOSPHONIC DIESTER DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256087-A1 | Phosphonic acid diester compounds | ACAT2, ACAT1, ACP1 | EGFR 1938/4885CYP1A2 1988/4885POLB 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.